3D Printed Muscle Tissues for Drug Discovery With Mantarray™ Platform by Curi Bio

by Natalia Honchar    Contributor        Biopharma insight / Biopharma Insights

Disclaimer: All opinions expressed by Contributors are their own and do not represent those of their employers, or BiopharmaTrend.com.
Contributors are fully responsible for assuring they own any required copyright for any content they submit to BiopharmaTrend.com. This website and its owners shall not be liable for neither information and content submitted for publication by Contributors, nor its accuracy.

   687    Comments 0
Topics: Emerging Technologies   

Curi Bio, a developer of human stem cell-based platforms for drug discovery, announced the commercial launch of the Mantarray™ platform for human-relevant 3D heart and skeletal engineered muscle tissue contractility analysis. Curi’s Mantarray platform can serve for the discovery of new therapeutics by providing parallel analysis of 3D EMTs with adult human-like functional profiles of healthy and disease models.

3D bioprinting

Image credit: luplupme iStock

 

Continue reading

This content available exclusively for BPT Mebmers

Topics: Emerging Technologies   

Share this:          

Comments:

There are no comments yet. You can be the first.

Leave a Reply

Your email address will not be published. Required fields are marked *

SHARE